Enjoy complimentary customisation on priority with our Enterprise License!
This market research study identifies AstraZeneca, Gilead, Novartis, and Pfizer as the leading players in the global coronary artery disease therapeutics market. A comprehensive analysis of this market is also presented by drug class (beta-blockers, calcium channel blockers, nitrates, ACE inhibitors, and others) and by geography (the Americas, APAC, and EMEA).
The incidence of chronic diseases such as diabetes, obesity, and high blood pressure is increasing across the globe. This creates a huge economic burden on the global healthcare system. Our research analysis on the global coronary artery disease therapeutics market has identified that the increase in the number of chronic diseases will be one of the major factors that will have a positive impact on this market’s growth during the next few years. A large number of patients are experiencing a low quality of life due to the uncontrolled blood sugar level. This can result in death. The lack of awareness and treatment facilities in Africa is resulting in an increased number of diabetic patients. According to the studies, countries such as China, India, and the US have the largest number of diabetic patients. This will further boost the demand for coronary artery disease therapeutics. Based on the coronary artery disease therapeutics industry analysis, this market will grow at a CAGR of more than 5% by 2021.
The fragmented nature of the market results in a division of profits among too many participants. This leaves the participants with minimal economic benefits. As a result, the coronary artery disease therapeutics market is witnessing a growth in the number of strategic alliances and acquisitions. In addition to acquisitions, the vendors are also focusing on entering into partnerships and are also forming joint ventures to develop new and better drugs.
The coronary artery disease therapeutics market is highly competitive and is characterized by the presence of a large number of large, small, and medium-sized vendors. The vendors are increasingly competing against each other based on factors such as aggressive pricing, product efficacy, limited side effects, rich pipeline, and operational base. The rise in the number of mergers and acquisitions, product extensions, and the rising investments in R&D activities will strengthen the market’s competitive environment.
Key vendors in this market are
Other prominent vendors in the market include Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Mylan, and Teva Pharmaceutical Industries
Beta-blockers drugs reduce the blood pressure and heart rate by blocking the effect of stress hormones such as adrenaline. Acebutolol, atenolol, carvedilol, labetalol, metoprolol, penbutolol, pindolol, and propranolol are some of the common beta-blockers that are used for the treatment of cardiovascular diseases. The beta-blockers drug class is highly preferred over other drug classes because they enable the damaged heart to work more effectively. This, in turn, will stimulate the coronary artery disease treatment market growth in this segment.
Based on the coronary artery disease therapeutics market regional outlook, the consumption of drugs for cardiovascular disease (CAD) in the Americas is increasing due to the rising incidences of heart disease in the region. The region is heavily investing in the healthcare sector, which in turn, will drive the coronary artery disease therapeutics market’s growth in the region. The US is the major revenue generator in the region due to the presence of the pharmaceutical giants and the high prevalence rate of CAD.
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MARKET LANDSCAPE
PART 06: PIPELINE LANDSCAPE
PART 07: MARKET SEGMENTATION BY DRUG CLASS
PART 08: REGIONAL LANDSCAPE
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
PART 14: KEY VENDORS
PART 15: APPENDIX
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.